HTGM HTG MOLECULAR DIAGNOSTICS

HTG Molecular Diagnostics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Tuesday, August 11

HTG Molecular Diagnostics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Tuesday, August 11

TUCSON, Ariz., Aug. 05, 2020 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2020 after the market close on Tuesday, August 11, 2020. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

Conference Call & Webcast Details  
Date:Tuesday, August 11
Time:4:30 pm Eastern Time
Toll Free:877-407-0789
International:201-689-8562
Conference ID:13706480
Webcast: 

About HTG

HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact:

Ashley R. Robinson

LifeSci Advisors, LLC

Phone: (617) 430-7577

Email: 

 

EN
05/08/2020

Underlying

HTGMHTG MOLECULAR DIAGNOSTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HTG MOLECULAR DIAGNOSTICS

 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG to Highlight the Advantages of its Drug Discovery Engine at the 20...

HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach ...

May 18, 2023 1 EN
 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG Highlights the Advantages of Its Drug Discovery Engine

HTG Highlights the Advantages of Its Drug Discovery Engine TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG’s objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostical...

May 16, 2023 1 EN
 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provi...

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG...

May 10, 2023 1 EN
 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG Provides Update on Drug Discovery Partnering Initiative

HTG Provides Update on Drug Discovery Partnering Initiative TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG’s proprietary RNA profiling technologies, function...

April 25, 2023 1 EN
 PRESS RELEASE
Free
HTGM HTG MOLECULAR D...

HTG Announces Key First Quarter Milestone Achievements for Drug Discov...

HTG Announces Key First Quarter Milestone Achievements for Drug Discovery TUCSON, Ariz., April 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced the achievement of three significant drug discovery business milestones in the first quarter of 2023. As reported in January 2023, HTG filed a patent application on December 28, 2022, which included claims directed toward specific compounds, pharmaceutical compositions and methods of treating or preventing disease by administration ...

April 18, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch